Full Professor(heuristic)

Colorectal Cancer Treatments and Studies · Oncology

Compare more Oncology professors.

h-index74
i10-index178
Publications893
Citations36,351

Grants

4 total · 3 active

NIH #R01CA296285

Targeting the Epidermal Growth Factor Receptor (EGFR) to Revert Trastuzumab Deruxtecan Resistance in HER2-low Colorectal Cancer.

Active
Amount
$400K–$500K
Period
2025-08-01 → 2030-07-31
PIs
2

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #R01CA288880

Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer

Active
Amount
$400K–$500K
Period
2024-03-01 → 2029-02-28
PIs
2

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #R21CA292178

Targeting Chromosomal Instability in the Evolution of Resistance to Matched Therapies Against Colorectal Cancer to Extend Treatment Response

Active
Amount
$200K–$300K
Period
2025-03-01 → 2027-02-28
PIs
1

Awarded at SLOAN-KETTERING INST CAN RESEARCH

Active grants are a starting point, not proof of an opening. Confirm recruiting and funding with the professor, current students, and your written offer. Learn how to verify PhD funding →

All Grants

4 total · 3 active

NIH #R01CA296285

Targeting the Epidermal Growth Factor Receptor (EGFR) to Revert Trastuzumab Deruxtecan Resistance in HER2-low Colorectal Cancer.

Active
Amount
$400K–$500K
Period
2025-08-01 → 2030-07-31
PIs
2

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #R01CA288880

Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer

Active
Amount
$400K–$500K
Period
2024-03-01 → 2029-02-28
PIs
2

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #R21CA292178

Targeting Chromosomal Instability in the Evolution of Resistance to Matched Therapies Against Colorectal Cancer to Extend Treatment Response

Active
Amount
$200K–$300K
Period
2025-03-01 → 2027-02-28
PIs
1

Awarded at SLOAN-KETTERING INST CAN RESEARCH

NIH #R01CA233736

Exploiting the distinct genomics and signaling of colorectal cancers to effectively target ERK

Amount
$500K–$600K
Period
2018-12-10 → 2023-11-30
PIs
1

Awarded at SLOAN-KETTERING INST CAN RESEARCH

Recent Public Signals

  1. New paper: Table S5 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with <i>BRAF</i>-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation2026-06-17
  2. New NIH award: Targeting the Epidermal Growth Factor Receptor (EGFR) to Revert Trastuzumab Deruxtecan Resistance in HER2-low Colorectal Cancer.2025-08-01
  3. New NIH award: Targeting Chromosomal Instability in the Evolution of Resistance to Matched Therapies Against Colorectal Cancer to Extend Treatment Response2025-03-01

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

Data Freshness

  • Publications as of 2026-07-09
  • Grants as of 2026-08-30

Data may not be current

Find elsewhere

Institution / lab homepage Search on ResearchGate

ORCID: 0000-0002-7233-5454

Professor Insights

Career Trajectory